Testimonials

“Abzena has been crucial in advancing and validating our technology and programs. The team is very thoughtful and has strong troubleshooting skills and maintains a high standard in generating quality data with integrity. We highly recommend working with Abzena.”

Shiva Bhowmik, PhD, COO of TRIO Pharmaceuticals, Inc.

“Sonnet and Abzena has had a productive working relationship for years. This success has been based upon Abzena’s excellent science and most importantly the abilities of their project management team.  I would also like to acknowledge Abzena’s scientific technical staff which has made many excellent suggestions and extra efforts contributing to the success of our projects.  I hope to continue my interactions with Abzena’s project managers and scientists in the future for all of Sonnet projects.”

Susan Dexter, CTO of Sonnet BioTherapeutics

“We worked with the Abzena team for the design and the initial production of both the mAb and the antibody-chelator conjugate to support our R&D programs. We had a productive and valuable interaction with a highly skilled scientific team and we benefited from the flexibility of the services at this early stage of development. ʺ

Tina Bjørnlund Bønsdorff, CSO of Oncoinvent AS

“We required a partner who not only shared our commitment to innovation but also possessed the deep technical expertise necessary to guide us through the complexities of ADC development. Abzena has been that partner for us. From the initial stages of linker payload design to the final steps of regulatory submission, their team has demonstrated exceptional proficiency and dedication. Working with Abzena, we have been impressed by their ability to integrate sophisticated design with rigorous analytical validation, all while maintaining a clear focus on regulatory compliance. Their proactive communication and adaptability have been particularly invaluable, ensuring that our projects not only meet but exceed the rigorous standards required in our field.”

“I had the pleasure of working with Abzena’s Cambridge, UK team on a variety of in vitro pharmacology projects, ranging from cell-based assays to Biacore kinetic analysis. I found the team to be professional, reliable, and excellent partners. Given the virtual nature of the company I work for, we rely on strong partnerships in order to produce quality data to allow us to make strategic program decisions. The Abzena team was instrumental in providing timely, high-quality data that impacted our decision-making. I would highly recommend this team for all your preclinical pharmacology needs.”

“I’ve never had a CRO project go this smoothly and the ADCs delivered were very high quality. I’m confident that my client will put Abzena at the top of their list for future ADC projects. ”

David Jackson, Pharmaceutical Consultant & ADC Expert

“We are very excited to have dosed our first patient in our first-in-human study of our novel TM4SF1 ADC, AGX101. Throughout the development of AGX101, Abzena has worked closely with us to achieve successful GMP manufacturing and quality control. We could not have reached this milestone without Abzena’s expertise, cooperation, and support. Both companies have extensive expertise in their respective fields and an aligned mission, and we look forward to continuing our partnership to ensure that AGX101 is available to meet the needs of clinical cancer patients. We are delighted that Abzena shares our vision that no one should die of cancer.”